Hostname: page-component-586b7cd67f-l7hp2 Total loading time: 0 Render date: 2024-11-24T06:30:13.703Z Has data issue: false hasContentIssue false

3444 Development of human engineered cardiac tissue (hECT)-based screening assay to explore cardiac contractile properties in response to pharmacological challenge with proarrhythmic drugs

Published online by Cambridge University Press:  26 March 2019

Francesca Stillitano
Affiliation:
Mount Sinai School of Medicine; Icahn School of Medicine at Mount Sinai; Institute of Cardiometabolism and Nutrition (ICAN); Icahn School of Medicine at Mount Sinai
Irene C. Turnbull
Affiliation:
Mount Sinai School of Medicine; Icahn School of Medicine at Mount Sinai; Institute of Cardiometabolism and Nutrition (ICAN); Icahn School of Medicine at Mount Sinai
Jaydev Dave
Affiliation:
Mount Sinai School of Medicine; Icahn School of Medicine at Mount Sinai; Institute of Cardiometabolism and Nutrition (ICAN); Icahn School of Medicine at Mount Sinai
Jean-Sébastien Hulot
Affiliation:
Mount Sinai School of Medicine; Icahn School of Medicine at Mount Sinai; Institute of Cardiometabolism and Nutrition (ICAN); Icahn School of Medicine at Mount Sinai
Roger J. Hajjar
Affiliation:
Mount Sinai School of Medicine; Icahn School of Medicine at Mount Sinai; Institute of Cardiometabolism and Nutrition (ICAN); Icahn School of Medicine at Mount Sinai
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

OBJECTIVES/SPECIFIC AIMS: The goals of this study were (1) to evaluate the effect of proarrhythmic drugs on calcium transient and (2) to use three-dimensional human engineered cardiac tissue (hECT) technology to evaluate cardiac contractile properties in response to pharmacological challenge with proarrhythmic drugs. METHODS/STUDY POPULATION: Calcium transient was measured in subject-specific iPSC-CMs by using the IonOptix system in Sotalol treated vs. untreated conditions. We fabricated human engineered cardiac tissues (hECT) in a custom designed bioreactor using low- and high-sentitive subject-specific iPSC-CMs. Contractile function of the hECT was evaluated at baseline and after Sotalol [300 µM] administration. The change in beat rate was recorded under spontaneous beating conditions; changes in other twitch parameters, including time to relaxation, were recorded under electrical stimulation. Time to relaxation served as an indicator of action potential duration (APD), which has a temporal correlation with the QT interval. RESULTS/ANTICIPATED RESULTS: The low-sensitive iPSC-CM showed a considerable drop in overall peak height of the calcium transient, in the presence of 100 µM Sotalol. The high-sensitive line, however, showed a more pronounced drop in peak height. Sotalol treatment also induced a more pronounced increase in the exponential decay time constant (tau) in the high-sensitive line compared to the low-sensitive line. The hECT fabricated with high sensitive hiPSC-CM showed a larger decrease in spontaneous beat rate in response to Sotalol (0.41 vs 0.23 fold decrease), with a higher increase in time to relaxation (1.8 vs 1.3 fold increase), compared to hECT from low sensitive hiPSC-CM. Moreover, while the low-sensitive hECT showed a positive correlation between time to relaxation and developed force, as expected after Sotalol stimulation; the high-sensitive hECT failed to show a positive inotropic response. DISCUSSION/SIGNIFICANCE OF IMPACT: Our findings suggest subject-specific iPSC-CMs and hECT, can be used to model functional abnormalities observed in diLQTS in response to Sotalol, and offer novel insights into human-based screening assays for toxic drug reactions. Success of this study may help identify key components underlying diLQT susceptibility to ultimately develop novel therapeutic agents.

Type
Basic/Translational Science/Team Science
Creative Commons
Creative Common License - CCCreative Common License - BYCreative Common License - NCCreative Common License - ND
This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (http://creativecommons.org/licenses/by-ncnd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is unaltered and is properly cited. The written permission of Cambridge University Press must be obtained for commercial re-use or in order to create a derivative work.
Copyright
© The Association for Clinical and Translational Science 2019